Wednesday, July 8, 2026

Patent intelligence · US

US 6239110

Synthetic analogs of thrombospondin and therapeutic use thereof

expired A61KA61K38/00
Status expired
Linked drugs 3
Pipeline programs 6
Years to expiry 0
Applicant portfolio 34
Patent details — US 6239110

Quick answer

US 6239110 (Synthetic analogs of thrombospondin and therapeutic use thereof) is held by W.R. Grace & Co.-Conn.. Status: expired. Granted May 29, 2001. Expires May 24, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
9
CPC classes
A61K, A61K38/00

More from W.R. Grace & Co.-Conn.

Related pharmaceutical patents in our USPTO index.

  1. US 12414943

    Nimodipine parenteral administration

    Grace Therapeutics U.S., Inc. · Expires Sep 11, 2045

    granted
  2. US 12049487

    Universal chimeric antigen receptor T-cell preparation technique

    GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. · Expires Jul 25, 2044

    granted
  3. US 11840575

    Engineered immune cells targeting BCMA and their uses thereof

    GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. · Expires Dec 7, 2043

    granted
  4. US 11484501

    Mechanochemical activated dry amorphisation by milling equilibrium between ap mesoporous silica

    Grace GmbH · Expires Oct 27, 2042

    granted
  5. US 11478424

    Mechanochemcial activated dry amorphisation by milling equilibrium between AP mesoporous silica

    Grace GmbH · Expires Oct 20, 2042

    granted
  6. US 11478420

    Vaginal probiotic products and related processes

    Grace Procurements LLC · Expires Oct 20, 2042

    granted
  7. US 11291672

    Betamethasone oral spray formulation and method of use to treat ataxia

    GRACE THERAPEUTICS INC. · Expires Mar 31, 2042

    granted
  8. US 11052029

    Cation compatible metal oxides and oral care compositions containing the metal oxides

    W.R. Grace & Co.-Conn. · Expires Jul 1, 2041

    granted

Frequently asked questions

What is US patent 6239110?

US 6239110 (Synthetic analogs of thrombospondin and therapeutic use thereof) is held by W.R. Grace & Co.-Conn.. Status: expired. Granted May 29, 2001. Expires May 24, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 6239110?

W.R. Grace & Co.-Conn. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 34 pharmaceutical patents for this assignee.

When does US 6239110 expire?

Our index shows an expiration date of May 24, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.